News/ News/ R&D Galecto raises $64m to finance EU filing for inhaled IPF drug Richard Staines Galecto, idiopathic pulmonary fibrosis, IPF, respiratory diseases 0 Comment Privately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs Share X Galecto raises $64m to finance EU filing for inhaled IPF drug https://pharmaphorum.com/news/galecto-raises-64m-to-finance-eu-filing-for-inhaled-ipf-drug/